Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

por Mahalingam, D, Wilding, G, Denmeade, S, Sarantopoulas, J, Cosgrove, D, Cetnar, J, Azad, N, Bruce, J, Kurman, M, Allgood, V E, Carducci, M
Publicado 2016

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

por Cavenagh, J, Oakervee, H, Baetiong-Caguioa, P, Davies, F, Gharibo, M, Rabin, N, Kurman, M, Novak, B, Shiraishi, N, Nakashima, D, Akinaga, S, Yong, K
Publicado 2017